Skip to main content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Antimicrob Agents Chemother. 1988 Jun; 32(6): 802–806.
doi: 10.1128/aac.32.6.802
PMCID: PMC172286
PMID: 3046481

Randomized clinical trial of rifampin-trimethoprim and sulfamethoxazole-trimethoprim in the treatment of localized urinary tract infections.

G E Stein, D Gurwith, and M Gurwith
Author information Copyright and License information PMC Disclaimer

Abstract

To investigate whether 10 days of rifampin-trimethoprim (RIF-TMP) or 6 weeks of sulfamethoxazole-trimethoprim (SMX-TMP) would decrease the relapse rate in patients with acute uncomplicated upper urinary tract infections in comparison with 10 days of SMX-TMP, we randomized 189 patients to receive RIF-TMP or SMX-TMP in a ratio of 1:2. After the site of infection was established by the antibody-coated bacterium (ACB) test, patients with upper-tract infections who received SMX-TMP were again randomized and received either a total of 6 weeks or 10 days of therapy. All patients who received RIF-TMP were treated for 10 days. Clinical and microbiological evaluations were repeated at 2 and 6 weeks posttreatment. Eighty-five patients (54 ACB positive) received 10 days of RIF-TMP, 71 patients (45 ACB positive) received 10 days of SMX-TMP, and 18 patients (18 ACB positive) received 6 weeks of SMX-TMP. The overall recurrence rates in patients who received 10 days of therapy were 32% for RIF-TMP and 23% for SMX-TMP (P = 0.13). There were 12 (14%) relapses in the RIF-TMP group compared with 2 (3%) relapses in the SMX-TMP group (P = 0.01). In patients with upper-tract infections, the relapse rates were not statistically significantly different (P = 0.13). There were two (11%) recurrences (one relapse and one reinfection) in the 6-week treatment group. This 6% relapse rate was not different from the 4% relapse rate observed in patients with upper-tract infections who received 10 days of SMX-TMP. The number of patients who discontinued treatment because of an adverse effect in the 6-week SMX-TMP treatment group was significantly greater than those in the 10-day SMX-TMP treatment group (P=0.003) and the RIF-TMP treatment group (P=0.05). Ten days of SMX-TMP was as effective as 6 weeks of SMP-TMP or 10 days of RIF-TMP in the treatment of uncomplicated upper urinary tract infections and caused the fewest untoward effects.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (976K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

 
icon of scanned page 802
802
icon of scanned page 803
803
icon of scanned page 804
804
icon of scanned page 805
805
icon of scanned page 806
806
 

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  • Acocella G, Scotti R. Kinetic studies on the combination rifampicin-trimethoprim in man. I. Absorption and urinary excretion after administration to healthy volunteers of single doses of the two compounds alone and in combination, and of the combination over a period of 1 week. J Antimicrob Chemother. 1976 Sep;2(3):271–277. [PubMed] [Google Scholar]
  • Adachi T, de Almeida TR. Controlled clinical trial of a rifampicin- trimethoprim combination (Rifaprim) and cotrimoxazole in patients with chronic urinary tract infections. J Int Med Res. 1979;7(2):132–137. [PubMed] [Google Scholar]
  • Arioli V, Berti M, Carniti G, Rossi E. Interaction between rifampicin and trimethoprim in vitro and in experimental infections. J Antimicrob Chemother. 1977 Jan;3(1):87–94. [PubMed] [Google Scholar]
  • Bourgault AM, Forward KR, Ronald AR, Harding GK, Thomson M, Grey G. Trimethoprim-rifampin, a new combination agent: efficacy in localized urinary infection and influence on microflora. Antimicrob Agents Chemother. 1981 Apr;19(4):513–518. [PMC free article] [PubMed] [Google Scholar]
  • Brooks D, Maudar A. Pathogenesis of the urethral syndrome in women and its diagnosis in general practice. Lancet. 1972 Oct 28;2(7783):893–898. [PubMed] [Google Scholar]
  • Brumfitt W, Dixson S, Hamilton-Miller JM. Use of rifampin for the treatment of urinary tract infections. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S573–S582. [PubMed] [Google Scholar]
  • Fang LS, Tolkoff-Rubin NE, Rubin RH. Efficacy of single-dose and conventional amoxicillin therapy in urinary-tract infection localized by the antibody-coated bacteria technic. N Engl J Med. 1978 Feb 23;298(8):413–416. [PubMed] [Google Scholar]
  • Farrell W, Wilks M, Drasar FA. The action of trimethoprim and rifampicin in combination against Gram-negative rods resistant to gentamicin. J Antimicrob Chemother. 1977 Sep;3(5):459–462. [PubMed] [Google Scholar]
  • GALLAGHER DJ, MONTGOMERIE JZ, NORTH JD. ACUTE INFECTIONS OF THE URINARY TRACT AND THE URETHRAL SYNDROME IN GENERAL PRACTICE. Br Med J. 1965 Mar 6;1(5435):622–626. [PMC free article] [PubMed] [Google Scholar]
  • Gargan RA, Brumfitt W, Hamilton-Miller JM. Antibody-coated bacteria in urine: criterion for a positive test and its value in defining a higher risk of treatment failure. Lancet. 1983 Sep 24;2(8352):704–706. [PubMed] [Google Scholar]
  • Gleckman R. A critical review of the antibody-coated bacteria test. J Urol. 1979 Dec;122(6):770–771. [PubMed] [Google Scholar]
  • Goldstein BP, Ripamonti IF, Bolzoni G, Carniti G, Arioli V. Rifampin plus trimethoprim: bactericidal activity and suppression of resistance in human urine in vitro. Antimicrob Agents Chemother. 1979 Dec;16(6):736–742. [PMC free article] [PubMed] [Google Scholar]
  • Grüneberg RN, Emmerson AM. The interactions between rifampicin and trimethoprim: an in vitro study. J Antimicrob Chemother. 1977 Sep;3(5):453–457. [PubMed] [Google Scholar]
  • Grüneberg RN, Emmerson AM. Prevention of emergence of bacterial resistance by combination of two antibiotics: rifampicin and trimethoprim. J Antimicrob Chemother. 1980 May;6(3):349–356. [PubMed] [Google Scholar]
  • Gurwith MJ, Stein GE, Gurwith D. Prospective comparison of amoxicillin-clavulanic acid and cefaclor in treatment of uncomplicated urinary tract infections. Antimicrob Agents Chemother. 1983 Nov;24(5):716–719. [PMC free article] [PubMed] [Google Scholar]
  • Jones SR, Smith JW, Sanford JP. Localization of urinary-tract infections by detection of antibody-coated bacteria in urine sediment. N Engl J Med. 1974 Mar 14;290(11):591–593. [PubMed] [Google Scholar]
  • Kerry DW, Hamilton-Miller JM, Brumfitt W. Trimethoprim and rifampicin: in vitro activities separately and in combination. J Antimicrob Chemother. 1975 Dec;1(4):417–427. [PubMed] [Google Scholar]
  • Kosmidis J, Giamarellou H, Papadakis M, Eliades E, Daikos GK. Rifaprim in urinary tract infection: a comparison with co-trimoxazole. J Antimicrob Chemother. 1983 Mar;11(3):239–244. [PubMed] [Google Scholar]
  • Kulasinghe HP, Cushing AH, Reed WP. Role of antibody-coated bacteria in the management of urinary tract infections. South Med J. 1977 Nov;70(11):1270–1272. [PubMed] [Google Scholar]
  • Lyons RW. Orange contact lenses from rifampin. N Engl J Med. 1979 Feb 15;300(7):372–373. [PubMed] [Google Scholar]
  • MOND NC, PERCIVAL A, WILLIAMS JD, BRUMFITT W. PRESENTATION, DIAGNOSIS, AND TREATMENT OF URINARY-TRACT INFECTIONS IN GENERAL PRACTICE. Lancet. 1965 Mar 6;1(7384):514–516. [PubMed] [Google Scholar]
  • Mundt KA, Polk BF. Identification of site of urinary-tract infections by antibody-coated bacteria assay. Lancet. 1979 Dec 1;2(8153):1172–1175. [PubMed] [Google Scholar]
  • Palminteri R, Sassella D. Double-blind multicenter trial of a rifampicin-trimethoprim combination and rifampicin alone in urinary tract infections. Chemotherapy. 1979;25(3):181–188. [PubMed] [Google Scholar]
  • Rubin RH, Fang LS, Jones SR, Munford RS, Slepack JM, Varga PA, Onheiber L, Hall CL, Tolkoff-Rubin NE. Single-dose amoxicillin therapy for urinary tract infection. Multicenter trial using antibody-coated bacteria localization technique. JAMA. 1980 Aug 8;244(6):561–564. [PubMed] [Google Scholar]
  • Santoro J, Kaye D. Recurrent urinary tract infections. Pathogenesis and management. Med Clin North Am. 1978 Sep;62(5):1005–1020. [PubMed] [Google Scholar]
  • Skolnick JL, Stoler BS, Katz DB, Anderson WH. Rifampin, oral contraceptives, and pregnancy. JAMA. 1976 Sep 20;236(12):1382–1382. [PubMed] [Google Scholar]
  • Stamm WE, Counts GW, Running KR, Fihn S, Turck M, Holmes KK. Diagnosis of coliform infection in acutely dysuric women. N Engl J Med. 1982 Aug 19;307(8):463–468. [PubMed] [Google Scholar]
  • Stamm WE, McKevitt M, Counts GW. Acute renal infection in women: treatment with trimethoprim-sulfamethoxazole or ampicillin for two or six weeks. A randomized trial. Ann Intern Med. 1987 Mar;106(3):341–345. [PubMed] [Google Scholar]
  • Stamm WE, Wagner KF, Amsel R, Alexander ER, Turck M, Counts GW, Holmes KK. Causes of the acute urethral syndrome in women. N Engl J Med. 1980 Aug 21;303(8):409–415. [PubMed] [Google Scholar]
  • Thomas V, Shelokov A, Forland M. Antibody-coated bacteria in the urine and the site of urinary-tract infection. N Engl J Med. 1974 Mar 14;290(11):588–590. [PubMed] [Google Scholar]
Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)
-